Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized - Summary - MDSpire

Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized

  • By

  • Sumit Sharma

  • Phoebe Lin

  • Allen Hu

  • Eric B. Suhler

  • Meike Pauly-Evers

  • William Holmes

  • Zeinab Barekati

  • Daniela Willen

  • Lachlan Macgregor

  • Laura Steeples

  • Zdenka Haskova

  • Derrick Feenstra

  • David Silverman

  • Benedicte Passemard

  • Sascha Fauser

  • Marina Mesquida

  • May 1, 2026

  • 0 min

Share

Objective:

To evaluate the safety, tolerability, and preliminary effects of intravitreal vamikibart in patients with uveitic macular edema (UME) secondary to noninfectious uveitis (NIU), focusing on primary endpoints such as visual acuity and macular edema reduction.

Key Findings:
  • Vamikibart demonstrated a favorable safety profile with limited systemic exposure.
  • Preliminary effects indicated potential improvements in visual acuity (specific metrics needed) and reduction in macular edema.
  • Sustained IL-6 suppression was observed, particularly at the 0.25 mg dose.
Interpretation:

The results suggest that vamikibart may be a promising targeted therapy for UME, particularly in overcoming limitations of current treatments such as systemic immunomodulators and corticosteroids.

Limitations:
  • The study was open-label and uncontrolled, which may limit the robustness of the findings and their applicability to broader populations.
  • The small sample size and short duration of follow-up may affect the generalizability of results.
Conclusion:

Vamikibart shows potential as a novel treatment for UME, warranting further investigation in larger, controlled trials to confirm efficacy and safety.

Original Source(s)

Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized

  • by Sumit Sharma, Phoebe Lin, Allen Hu, Eric B. Suhler, Meike Pauly-Evers, William Holmes, Zeinab Barekati, Daniela Willen, Lachlan Macgregor, Laura Steeples, Zdenka Haskova, Derrick Feenstra, David Silverman, Benedicte Passemard, Sascha Fauser, Marina Mesquida

  • May 1, 2026

Related Content

Video: Avoiding Mistakes in Posterior Uveitis Care

Quan Dong Nguyen, MD, discusses how retina specialists can refine diagnostic accuracy, simplify testing, and use systemic therapies safely.

Case Report: Bilateral panuveitis with serous ciliary body and choroidal detachment associated with ulcerative colitis

Efficacy of the 0.18 mg fluocinolone acetonide intravitreal implant in treating macular edema linked to non-infectious uveitis: Insights from a real-world analysis